Jazz Pharmaceuticals PLC (JAZZ) Receives $182.49 Consensus Target Price from Analysts

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has been assigned a consensus recommendation of “Buy” from the twenty-four analysts that are presently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $182.49.

Several research analysts have recently weighed in on the company. Piper Jaffray Companies restated a “buy” rating and set a $201.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, March 1st. HC Wainwright set a $160.00 target price on Jazz Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, May 9th. ValuEngine cut Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. Seaport Global Securities set a $175.00 target price on Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, April 6th. Finally, Zacks Investment Research upgraded Jazz Pharmaceuticals from a “hold” rating to a “buy” rating and set a $189.00 target price on the stock in a report on Thursday, May 31st.

Shares of Jazz Pharmaceuticals stock traded up $1.42 on Friday, hitting $177.23. 406,435 shares of the company were exchanged, compared to its average volume of 471,219. The stock has a market cap of $10.68 billion, a P/E ratio of 18.54, a P/E/G ratio of 0.91 and a beta of 0.96. Jazz Pharmaceuticals has a 1-year low of $128.58 and a 1-year high of $179.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.00 and a quick ratio of 2.88.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported $2.98 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.78 by $0.20. The business had revenue of $444.61 million for the quarter, compared to analysts’ expectations of $435.69 million. Jazz Pharmaceuticals had a return on equity of 23.78% and a net margin of 26.51%. The business’s revenue for the quarter was up 18.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.31 EPS. research analysts expect that Jazz Pharmaceuticals will post 11.65 EPS for the current fiscal year.

In other Jazz Pharmaceuticals news, CFO Matthew P. Young sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, June 1st. The stock was sold at an average price of $170.04, for a total value of $850,200.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $150.01, for a total value of $150,010.00. Following the completion of the sale, the chief executive officer now directly owns 293,542 shares in the company, valued at approximately $44,034,235.42. The disclosure for this sale can be found here. In the last three months, insiders sold 24,179 shares of company stock worth $3,965,975. 4.30% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Suntrust Banks Inc. raised its position in Jazz Pharmaceuticals by 6.9% in the first quarter. Suntrust Banks Inc. now owns 12,068 shares of the specialty pharmaceutical company’s stock valued at $1,821,000 after purchasing an additional 775 shares during the period. Allianz Asset Management GmbH raised its position in Jazz Pharmaceuticals by 2.2% in the first quarter. Allianz Asset Management GmbH now owns 111,701 shares of the specialty pharmaceutical company’s stock valued at $16,865,000 after purchasing an additional 2,422 shares during the period. Summit Trail Advisors LLC raised its position in Jazz Pharmaceuticals by 8,591.5% in the first quarter. Summit Trail Advisors LLC now owns 102,125 shares of the specialty pharmaceutical company’s stock valued at $102,000 after purchasing an additional 100,950 shares during the period. CIBC World Markets Inc. purchased a new stake in Jazz Pharmaceuticals in the first quarter valued at approximately $579,000. Finally, Xact Kapitalforvaltning AB raised its position in Jazz Pharmaceuticals by 2.6% in the first quarter. Xact Kapitalforvaltning AB now owns 14,606 shares of the specialty pharmaceutical company’s stock valued at $2,205,000 after purchasing an additional 374 shares during the period. 88.91% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Ruptured Biceps Tendon Ends Miguel Cabrera’s Season
Ruptured Biceps Tendon Ends Miguel Cabrera’s Season
Dodgers Getting Big Unexpected Lift from Three Players
Dodgers Getting Big Unexpected Lift from Three Players
What does legal betting mean for the baseball industry?
What does legal betting mean for the baseball industry?
Dodgers Use Nine Pitchers in Nine-Inning Game
Dodgers Use Nine Pitchers in Nine-Inning Game
Max Scherzer Throws Second Career Immaculate Inning
Max Scherzer Throws Second Career Immaculate Inning
Phillies Swept and Jake Arrieta Upset
Phillies Swept and Jake Arrieta Upset


Leave a Reply

 
© 2006-2018 BBNS.